Literature DB >> 9019487

Performance of small diameter synthetic vascular prostheses with confluent autologous endothelial cell linings.

L A Poole-Warren1, K Schindhelm, A R Graham, P R Slowiaczek, K R Noble.   

Abstract

Autologous grafts are superior to their synthetic counter-parts for grafting arteries smaller than 6-mm diameter both in terms of acute thrombogenicity and chronic intimal hyperplasia. Endothelial cell (EC) coating of the blood contacting surface may reduce thrombogenicity of synthetic small diameter vascular prostheses. In this study, the survival of EC monolayers on synthetic 4-mm diameter arterial prostheses over short-term implantations (< or = 6 weeks) was examined. Graft types examined were expanded polytetra-fluoroethylene (ePTFE) and microporous polyurethane (PU). Lumenal coverage with ECs was achieved by culturing ovine ECs on prostheses treated by either physical adsorption or covalent binding of ovine fibronectin (Fn). An ovine carotid interposition model was used to examine the performance of EC coated ePTFE and microporous PU over implantation periods of 1, 3, and 6 weeks. Outcomes assessed at the end of each experiment were graft patency, area covered by ECs, and thrombus free surface area (TFSA). Fn concentration, cell density at the time of coating and prostacyclin production in vitro were similar for both graft types. Occlusion occurred more frequently in unseeded grafts compared with EC coated grafts over 3 and 6 week implantation periods; however, the difference was not significant (p = 0.099). In prostheses precoated with ECs, approximately 40-60% of the surface area remained covered with endothelial-like cells following the first postoperative week. Recovery of EC layers occurred rapidly thereafter with 80-90% coverage at 3 weeks. TFSA remained low in comparison to EC cover in these prostheses until between 3 and 6 weeks postoperatively, suggesting a lag phase in recovery of EC function of seeded cells. In contrast, EC cover of unseeded prostheses only achieved 10-30% at 3 weeks, primarily by pannus EC ingrowth from the adjacent artery. TFSA of unseeded grafts increased in direct proportion to EC cover over time suggesting that there was no lag phase in function of these ingrowing cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9019487     DOI: 10.1002/(SICI)1097-4636(199602)30:2<221::AID-JBM12>3.0.CO;2-P

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  6 in total

1.  Effects of thermal annealing of segmented-polyurethane on surface properties, structure and antithrombogenicity.

Authors:  Atsuo Takahashi; Rio Kita; Makoto Kaibara
Journal:  J Mater Sci Mater Med       Date:  2002-03       Impact factor: 3.896

2.  Endothelial cells on plasma-treated segmented-polyurethane: adhesion strength, antithrombogenicity and cultivation in tubes.

Authors:  Y Kawamoto; A Nakao; Y Ito; N Wada; M Kaibara
Journal:  J Mater Sci Mater Med       Date:  1997-09       Impact factor: 3.896

3.  Co-expression of fibulin-5 and VEGF165 increases long-term patency of synthetic vascular grafts seeded with autologous endothelial cells.

Authors:  M Preis; J Schneiderman; B Koren; Y Ben-Yosef; D Levin-Ashkenazi; S Shapiro; T Cohen; M Blich; M Israeli-Amit; Y Sarnatzki; D Gershtein; R Shofti; B S Lewis; Y Shaul; M Y Flugelman
Journal:  Gene Ther       Date:  2015-12-24       Impact factor: 5.250

4.  Tissue responses to endovascular stent grafts for saccular abdominal aortic aneurysms in a canine model.

Authors:  Hyun Beom Kim; Young Ho Choi; Young Ho So; Seung-Kee Min; Hyo-Cheol Kim; Young Il Kim; Jae Hyung Park; Jin Wook Chung
Journal:  J Korean Med Sci       Date:  2012-10-02       Impact factor: 2.153

5.  Streptavidin binding and endothelial cell adhesion to biotinylated fibronectin.

Authors:  Charles C Anamelechi; Edward E Clermont; Melissa A Brown; George A Truskey; William M Reichert
Journal:  Langmuir       Date:  2007-11-07       Impact factor: 3.882

6.  In Vivo Application of Tissue-Engineered Veins Using Autologous Peripheral Whole Blood: A Proof of Concept Study.

Authors:  Michael Olausson; Vijay Kumar Kuna; Galyna Travnikova; Henrik Bäckdahl; Pradeep B Patil; Robert Saalman; Helena Borg; Anders Jeppsson; Suchitra Sumitran-Holgersson
Journal:  EBioMedicine       Date:  2014-09-22       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.